Alzheimer’s disease (AD) is increasingly prevalent worldwide, and disease‐modifying
treatments may soon be at hand; hence, now, more than ever, there is a need to develop …

Highlights • Protein biomarkers in cerebrospinal fluid now define Alzheimer’s disease (AD).
• New ultrasensitive techniques have enabled promising replication in blood. • This would …

Alzheimer's disease (AD) characterization has progressed from being indexed using clinical
symptomatology followed by neuropathological examination at autopsy to in vivo signatures …

… First authors Joel Simrén and Antoine Leuzy contributed … First authors Joel Simrén and Antoine
Leuzy contributed … First authors Joel Simrén and Antoine Leuzy contributed equally to this …

Plasma biomarkers related to amyloid, tau, and neurodegeneration (ATN) show great
promise for identifying these pathological features of Alzheimer’s Disease (AD) as shown by …

Background Neurologic manifestations are well-recognized features of coronavirus disease
2019 (COVID-19). However, the longitudinal association of biomarkers reflecting CNS …

Neuronal cell loss is a defining feature of Alzheimer’s disease (AD), but the underlying
mechanisms remain unclear. We xenografted human or mouse neurons into the brain of a mouse …

Introduction This study involved a parallel comparison of the diagnostic and longitudinal
monitoring potential of plasma glial fibrillary acidic protein (GFAP), total tau (t‐tau), …

The recent development of assays that accurately quantify neurofilament light, a neuronal
cytoskeleton protein, in plasma has generated a vast literature supporting that it is a sensitive, …

Introduction We tested how tube types (ethylenediaminetetraacetic acid [EDTA], serum, lithium
heparin [LiHep], and citrate) and freeze–thaw cycles affect levels of blood biomarkers for …